Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status approved
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 52076-6247; 62227-019; 68254-6234; 71052-559; 49884-283; 0054-0480; 0078-0566; 0078-0620; 0078-0627; 0378-3096; 0378-3097; 67877-721; 0054-0472; 70377-012; 65129-1324; 71796-012; 0078-0422; 0093-7767; 0093-7768; 49884-119; 51991-821; 63850-0062; 63850-0064; 70377-010; 70377-011; 63850-0059; 67877-718; 0054-0470; 17404-1027; 65727-064; 0078-0567; 51991-824; 63850-0058; 0378-0007; 0378-3098; 0054-0497; 65727-063; 0078-0594; 0078-0628; 49884-158; 0378-0005; 0378-3099; 67877-720; 0054-0471; 52076-6253; 62227-013; 70225-1103; 0078-0415; 0078-0417; 0078-0626; 0054-0482; 52076-6234; 63850-0063; 67877-719; 63850-0061; 0054-0481; 0054-0604; 49884-160; 51991-822; 63850-0060; 0378-0006; 70377-013; 65727-046; 0078-0414; 0093-7766; 49884-125; 49884-127; 49884-128; 49884-159; 51991-823
UNII 9HW64Q8G6G
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lung adenocarcinoma22.08.01.007; 16.19.01.0020.000153%Not Available
Lung carcinoma cell type unspecified stage IV22.08.01.019; 16.19.02.0060.000229%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.0250.000229%Not Available
Malignant ascites16.32.03.013; 07.07.01.0040.000153%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000306%Not Available
Mesenteric vein thrombosis24.01.08.004; 07.15.02.0130.000153%Not Available
Metastases to abdominal cavity16.22.02.010; 07.21.03.0060.000153%Not Available
Metastases to adrenals05.01.04.007; 16.22.02.0120.000306%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.005122%Not Available
Metastases to breast21.05.01.024; 16.22.02.0140.000229%Not Available
Metastases to kidney16.22.02.017; 20.01.04.0100.000459%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.001605%Not Available
Metastases to pleura16.22.02.022; 22.05.04.0020.000688%Not Available
Metastases to skin23.07.04.026; 16.22.02.0230.000612%Not Available
Metastases to the mediastinum22.09.03.009; 16.22.02.0270.000306%Not Available
Recurrent cancer16.16.01.0150.000535%Not Available
Sleep disorder due to general medical condition, insomnia type19.02.04.0040.000336%Not Available
Teeth brittle07.09.05.0150.000153%Not Available
Concomitant disease progression08.01.03.0640.001147%Not Available
Terminal state08.01.03.0790.000612%Not Available
Pancreatic mass07.18.02.0070.000413%Not Available
Ovarian cyst torsion21.11.01.016; 16.04.03.0070.000153%Not Available
Metastases to stomach07.21.03.007; 16.22.02.0260.000229%Not Available
Metastases to pancreas16.22.02.020; 07.21.09.0050.000382%Not Available
Renal cancer metastatic20.01.04.012; 16.08.02.0060.000229%Not Available
Gastric varices24.10.02.005; 09.01.06.013; 07.15.03.0040.000153%Not Available
Acquired dysfibrinogenaemia01.01.02.0150.000153%Not Available
Gastric antral vascular ectasia24.03.03.028; 07.15.04.0030.000382%Not Available
Metastases to chest wall15.09.03.018; 16.22.02.0150.000153%Not Available
Metastases to thorax22.08.03.001; 16.22.02.0280.000153%Not Available
The 29th Page    First    Pre   29 30 31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene